What's Happening?
FairJourney Bio (FJBio), a contract research organization, has opened a new cryo-electron microscopy (cryo-EM) structural biology facility in San Diego. This facility is part of FJBio's strategy to expand its presence in the U.S. market, complementing
its existing operations in San Francisco and Europe. The facility is equipped with advanced 300 kV cryo-EM infrastructure, including two ThermoFisher Titan Krios 5 systems, which allow for native-state structure determination of antibody-target complexes. This technology is integrated into FJBio's antibody discovery platform, providing detailed insights from epitope mapping to candidate selection. The services offered by the facility, which began in January 2026, aim to enhance the company's antibody discovery and biologic development portfolio by enabling scientists to visualize protein structures at atomic resolution.
Why It's Important?
The establishment of this facility marks a significant advancement in the field of structural biology, particularly in the early stages of drug discovery. By embedding structural insights at the start of the discovery process, FJBio aims to redefine the traditional role of structural biology, which has typically been a late-stage tool. This approach could lead to more informed decision-making in drug development, potentially accelerating the process and improving the success rate of new therapeutics. The facility's location in San Diego, a major biotech hub, positions FJBio to collaborate with leading researchers and institutions, further enhancing its capabilities and impact on the biotech industry.
